دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
A. John 1 & S. Popat1,2 *
doi : 10.1016/j.annonc.2023.06.010
Volume 34, Issue 10, October 2023, Pages 829-830
Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors
O. Adotévi
doi : 10.1016/j.annonc.2023.08.002
Volume 34, Issue 10, October 2023, Pages 831-832
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
A. Gonz?lez-Mart?n 1 , P. Harter 2 , A. Leary 3 , D. Lorusso4,5 , R. E. Miller 6,7 , B. Pothuri 8 , I. Ray-Coquard 9 , D. S. P. Tan 10,11,12,13 , E. Bellet14 , A. Oaknin 15 & J. A. Ledermann 16 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2023.07.011
Volume 34, Issue 10, October 2023, Pages 833-848
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
S. Loibl 1,2,3 , H. A. Azim, Jr 4 , T. Bachelot5 , P. Berveiller 6,7 , A. Bosch 8,9 , E. Cardonick 10 , C. Denkert 11 , M. J. Halaska12 , M. Hoeltzenbein 13 , A. L. V. Johansson 14,15 , C. Maggen 16 , U. R. Markert 17 , F. Peccatori 18 , P. Poortmans 19,20 , E. Saloustros 21 , C. Saura22 , P. Schmid23 , E. Stamatakis 24 , M. van den Heuvel-Eibrink 25 , M. van Gerwen26,27,28 , V. Vandecaveye29 , G. Pentheroudakis 30 , G. Curigliano 31,32 & F. Amant
doi : 10.1016/j.annonc.2023.08.001
Volume 34, Issue 10, October 2023, Pages 849-866
Treatment of evolving cancers will require dynamic decision support
M. A. R. Strobl 1,2y, J. Gallaher1y, M. Robertson-Tessi 1 , J. West1z & A. R. A. Anderson1 z
doi : 10.1016/j.annonc.2023.08.008
Volume 34, Issue 10, October 2023, Pages 867-884
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
K. Jhaveri 1,2 , L. D. Eli 3 , H. Wildiers4 , S. A. Hurvitz5 , A. Guerrero-Zotano 6 , N. Unni 7 , A. Brufsky8 , H. Park9 , J. Waisman10 , E. S. Yang 11 , I. Spanggaard12 , S. Reid 13 , M. E. Burkard14 , S. Vinayak 15 , A. Prat 16 , M. Arnedos17y, F.-C. Bidard18 , S. Loi 19,20 , J. Crown21 , M. Bhave 22 , S. A. Piha-Paul23 , J. M. Suga 24 , S. Chia 25 , C. Saura 26 , J. ?. Garcia-Saenz 27 , V. Gambardella 28 , M. J. de Miguel 29 , E. N. Gal-Yam30 , A. Rapael31 , S. M. Stemmer 32,33 , C. Ma 34 , A. B. Hanker 35 , D. Ye35 , J. W. Goldman36 , R. Bose 34 , L. Peterson34 , J. S. K. Bell 37 , A. Frazier3 , D. DiPrimeo 3 , A. Wong 3 , C. L. Arteaga35z & D. B. Solit
doi : 10.1016/j.annonc.2023.08.003
Volume 34, Issue 10, October 2023, Pages 885-898
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030☆
H. A. Parsons 1,2,3 x, T. Blewett4x, X. Chu5 , S. Sridhar 4 , K. Santos 1 , K. Xiong 4 , V. G. Abramson 6 , A. Patel1 , J. Cheng 4 , A. Brufsky 7 , J. Rhoades 4 , J. Force 8 , R. Liu 4 , T. A. Traina 9 , L. A. Carey 10 , M. F. Rimawi 11 , K. D. Miller 12 , V. Stearns 13 , J. Specht 14 , C. Falkson 15z, H. J. Burstein1,2,3 , A. C. Wolff 13 , E. P. Winer1,2,3y, N. Tayob5 , I. E. Krop 1,2,3y, G. M. Makrigiorgos 16 , T. R. Golub4 , E. L. Mayer 1,2,3 k & V. A. Adalsteinsson
doi : 10.1016/j.annonc.2023.08.004
Volume 34, Issue 10, October 2023, Pages 899-906
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
E. Felip1 , N. Altorki 2 , C. Zhou 3 , E. Vallières 4 , A. Mart?nez-Mart? 1 , A. Rittmeyer5 , A. Chella 6 , M. Reck7 , O. Goloborodko 8 , M. Huang9 , R. Belleli 10 , V. McNally 11 , M. K. Srivastava 9 , E. Bennett9 , B. J. Gitlitz 9 & H. A. Wakelee
doi : 10.1016/j.annonc.2023.07.001
Volume 34, Issue 10, October 2023, Pages 907-919
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1☆
B. Besse 1 , E. Felip2 , R. Garcia Campelo 3 , M. Cobo 4 , C. Mascaux5 , A. Madroszyk 6 , F. Cappuzzo7 , W. Hilgers8 , G. Romano 9 , F. Denis10 , S. Viteri11 , D. Debieuvre12 , D. Galetta 13 , E. Baldini 14 , M. Razaq15 , G. Robinet16 , M. Maio 17 , A. Delmonte18 , B. Roch 19 , P. Masson 20 , W. Schuette 21 , A. Zer 22 , J. Remon 1 , D. Costantini 23 , B. Vasseur 23 , R. Dziadziuszko 24 & G. Giaccone25 , on behalf of the ATALANTE-1 study group
doi : 10.1016/j.annonc.2023.07.006
Volume 34, Issue 10, October 2023, Pages 920-933
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe☆
A. Bayle 1,2,3,4,5 , J. Bonastre3,4 , D. Chaltiel 3,4 , N. Latino5 , E. Rouleau 6,7 , S. Peters 5,8 , M. Galotti 5 , G. Bricalli 5 , B. Besse 2,9y & R. Giuliani
doi : 10.1016/j.annonc.2023.06.011
Volume 34, Issue 10, October 2023, Pages 934-945
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors
M. A. Gouda 1 , M. I. Hu 2 , M. E. Cabanillas2 , J. Wu3,4 , F. Meric-Bernstam1 & V. Subbiah
doi : 10.1016/j.annonc.2023.07.002
Volume 34, Issue 10, October 2023, Pages 946-948
The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
T. Wei 1,y, D. Wang 2,y & P. Yuan
doi : 10.1016/j.annonc.2023.07.004
Volume 34, Issue 10, October 2023, Pages 948-949
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
P. Tarantino 1,2,3 , S. M. Tolaney 1,2 & G. Curigliano
doi : 10.1016/j.annonc.2023.07.003
Volume 34, Issue 10, October 2023, Pages 949-950
VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
P. A. Fasching 1, D. Slamon 2 , Z. Nowecki 3 , B. D. Kukielka-Budny 4 , D. Stroyakovskiy 5 , D. Yardley 6 , C. Huang 7 , A. Chan 8 , S. Chia 9 , M. Martin 10 , H. S. Rugo 11 , S. Loi 12 , S. A. Hurvitz 13 , M. Untch14 , K. Afenjar 15 , R. Fresco 16 , A. Danyliv17 , I. Ferrusi 18 , Z. Li19 & G. N. Hortobagyi
doi : 10.1016/j.annonc.2023.08.007
Volume 34, Issue 10, October 2023, Pages 951-953
